Zealand Pharma A/S (OTCMKTS:ZLDPF) Posts Quarterly Earnings Results, Beats Expectations By $1.45 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its quarterly earnings data on Thursday. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.45, Zacks reports. Zealand Pharma A/S had a return on equity of 17.56% and a net margin of 58.86%.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF traded down $1.35 during trading hours on Thursday, hitting $35.50. 515 shares of the stock were exchanged, compared to its average volume of 2,350. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The company has a market cap of $2.54 billion, a price-to-earnings ratio of 5.89 and a beta of 0.99. Zealand Pharma A/S has a 12-month low of $33.08 and a 12-month high of $83.12. The stock has a 50-day moving average of $38.85 and a 200 day moving average of $46.81.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZLDPF. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Zacks Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Hold”.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.